Search

Your search keyword '"Hooper, R"' showing total 1,074 results
Start Over Author "Hooper, R" Language english
1,074 results on '"Hooper, R"'

11. Novel PP2A-Activating Compounds in Neuroblastoma.

Author

Nazam, Nazia, Bownes, Laura V., Julson, Janet R., Quinn, Colin H., Erwin, Michael H., Marayati, Raoud, Markert, Hooper R., Shirley, Sorina, Stewart, Jerry E., Yoon, Karina J., Aye, Jamie, Ohlmeyer, Michael, and Beierle, Elizabeth A.

Subjects
PHOSPHORYLATION, PHENOMENOLOGICAL biology, ANTINEOPLASTIC agents, CELL proliferation, PHOSPHATASES, XENOGRAFTS, CELL motility, IN vivo studies, BIOCHEMISTRY, CELLULAR signal transduction, ESTERASES, CELL lines, GENE expression, ONCOGENES, SULFONAMIDES, CELL survival, NEUROBLASTOMA, PHARMACODYNAMICS
Abstract

Simple Summary: Neuroblastoma is the third most common type of childhood cancer but is responsible for over 15% of all pediatric cancer deaths. Children with advanced disease have less than a 50% survival rate and are in desperate need of new treatment options. Protein phosphatase 2A (PP2A) is a protein that inhibits tumors, but it is turned off in neuroblastoma. We have previously shown that we can activate PP2A in neuroblastoma with certain drugs and decrease tumor growth, but these drugs also affect the function of the immune system. We now have new small molecules that activate PP2A without upsetting the immune system. We observed a decrease in tumor growth, proliferation, and motility with our novel PP2A activators. We feel that a better understanding of how activating PP2A inhibits neuroblastoma will lead to better treatments for these children. Background: Neuroblastoma (NB) remains one of the deadliest pediatric solid tumors. Recent advancements aimed at improving outcomes have been insufficient, and patients with high-risk NB continue to have a poor prognosis. Protein phosphatase 2A (PP2A) is a tumor suppressor protein downregulated in many cancers, including NB. PP2A activation has been shown to affect the malignant phenotype in other solid tumors. The present studies aim to investigate the effects of two novel PP2A activators as a NB therapeutic. Methods: Four established NB cell lines and a patient-derived xenoline were utilized to study the effect on cell viability, proliferation, motility, and in vivo tumor growth using two novel tricyclic sulfonamide PP2A activators, ATUX-3364 and ATUX-8385. Results: ATUX-3364 and ATUX-8385 increased PP2A activity. These PP2A activators led to decreased viability, proliferation, and motility of NB cells. Treatment of animals bearing NB tumors with ATUX-3364 or ATUX-8385 resulted in decreased tumor growth in MYCN-amplified SK-N-BE(2) tumors. At the molecular level, PP2A-based reactivation led to dephosphorylation of MYCN-S62 and decreased MYCN protein expression. Conclusions: PP2A activators decreased NB cell viability, proliferation, and motility. In vivo experiments show that PP2A activators have more significant effects on tumorigenesis in MYCN-amplified tumors. Finally, phosphorylation of MYCN protein was decreased following treatment with novel sulfonamide PP2A activators. These data and mechanistic insights may be useful for developing new PP2A-based therapies that target MYCN for the treatment of NB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts

Author

Laura L. Stafman, Adele P. Williams, Raoud Marayati, Jamie M. Aye, Hooper R. Markert, Evan F. Garner, Colin H. Quinn, Shoeb B. Lallani, Jerry E. Stewart, Karina J. Yoon, Kimberly Whelan, and Elizabeth A. Beierle

Subjects
Medicine, Science
Abstract

Abstract Patient-derived xenografts (PDXs) provide an opportunity to evaluate the effects of therapies in an environment that more closely resembles the human condition than that seen with long-term passage cell lines. In the current studies, we investigated the effects of FAK inhibition on two neuroblastoma PDXs in vitro. Cells were treated with two small molecule inhibitors of FAK, PF-573,228 (PF) and 1,2,4,5-benzentetraamine tetrahydrochloride (Y15). Following FAK inhibition, cell survival and proliferation decreased significantly and cell cycle arrest was seen in both cell lines. Migration and invasion assays were used to determine the effect of FAK inhibition on cell motility, which decreased significantly in both cell lines in the presence of either inhibitor. Finally, tumor cell stemness following FAK inhibition was evaluated with extreme limiting dilution assays as well as with immunoblotting and quantitative real-time PCR for the expression of stem cell markers. FAK inhibition decreased formation of tumorspheres and resulted in a corresponding decrease in established stem cell markers. FAK inhibition decreased many characteristics of the malignant phenotype, including cancer stem cell like features in neuroblastoma PDXs, making FAK a candidate for further investigation as a potential target for neuroblastoma therapy.

Published
2019
Full Text
View/download PDF

14. Molecular characterisation of NAADP-gated two-pore channels

Author

Hooper, R.

Subjects
570
Abstract

Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent intracellular calcium (Ca2+)-mobilising second messenger implicated in a variety of physiological processes. Unusually, NAADP mediates Ca2+ release from acidic organelles, such as the lysosome, and not the endoplasmic reticulum. Recently, members of the voltagegated ion channel super-family, the two-pore channels (TPCs), have been identified as molecular targets of NAADP. The aim of this thesis is to investigate the molecular properties of these poorly characterised ion channels. In this study, I present the cloning of a novel TPC isoform from the sea urchin, an extensively used model organism for NAADP signalling, and the subsequent characterisation of the complete ancestral sea urchin TPC family. Sea urchin TPCs appeared to be Nglycosylated in an isoform-specific manner, displayed anomalous migration upon fractionation, similar to endogenous NAADP-binding proteins, and localised to the endo-lysosomal system. To characterise the properties of human TPCs, antibodies suitable for Western blot and immunocytochemistry analyses were identified. The topology of human TPCs was examined using in silico prediction methods, combined with fluorescence protease protection assays and the mapping of TPC antibody epitopes and N-glycosylation sites. Human TPCs conformed to a twelve transmembrane region model with cytosolic termini. The quaternary structure of TPCs was investigated using FRET analysis, sucrose density gradients, gel filtration, co-immunoprecipitation, and chemical cross-linking of both full-length TPCs and individual hydrophobic domains. TPCs likely assemble as dimers possibly within a high molecular weight protein complex. Finally, I show that the N-terminus of TPC1 regulates NAADP-mediated Ca2+ release and identify a potential physiological role for TPC2 in pigmentation.

Published
2011

15. The responsibility to implement 'The Responsibility to Protect'

Author

Hooper, R. S.

Subjects
327
Abstract

The Responsibility to Protect offers a morally based policy that places a new responsibility on the international community to protect populations from extremes of harm caused by governments. From the policy’s text, the reason for action seems to lie, most fundamentally, in an expression of ‘our common humanity’. However, The Responsibility to Protect does not offer any justification for its proposals. It responds to the question ‘what ought to be done?’ but answers the question ‘what can be done?’ leaving in between a gap in the moral credibility of action. The thesis explores what this lack of philosophical underpinning means to the persuasive power of the policy. The thesis then examines the claim of sovereignty as responsibility and finds it confused and incomplete and lacking the detail necessary for coherent implementation. It uses the Aristotelian square of opposition to investigate the tripartite nature of the new responsibilities to prevent and rebuild. Finally, the thesis investigates the policy’s apparent assumption that an ethically based policy of humanitarian intervention can be appropriately guided by the ethical rules of war. It asks if war and humanitarian intervention are the same thing and finds that they are not. It then explores the incoherence created by using the Just War Tradition for guide R2P. If The Responsibility to Protect offers no greater generation of will and effective action to humanitarian intervention than the current ad hoc process does, its establishment as UN policy becomes a pyrrhic victory. It will result in further anomalies in response by the UN, and consequent damage to the reputation and credibility of the UN as the guardian of international peace and security.

Published
2010

16. Development of techniques for the study of protein systems

Author

Hooper, R. J.

Subjects
572.8
Abstract

This dissertation descries work undertaken to investigate protein systems on nano- and micro-levels. The principal objective was the application of fluid dynamic gauging with simultaneous direct imaging of the changes in microstructure occurring during the cleaning of whey protein foulants. Laser confocal microscopy allowed images of the internal microstructure, on the micron and tens-of-microns scales, to be matched against the changing macro-properties of a whey protein film during cleaning, as measured by the gauge on the tens-of-microns scale. This work constitutes proof of concept; the successful capture of gauging and microscopy data displaying consistent, complementary phenomena proved the efficacy of the experimental concept. Achievement of this goal required first establishing the operating range within which use of the gauge caused minimal interference with the film being studied and, secondly, the development of a whey protein foulant that reproduced behavioural characteristics of fouling layers studied by previous researchers while also being suitable for microscopy. Both these objectives were achieved. That minimal interference range was established by comparing gauging cleaning profiles of particular deposits within duct flows against alternative cleaning profiles obtained by measuring the changing thermal resistances of the deposits. It was shown that the suitability of the operating regime was dependent on the capacity of the deposit to resist the suction pressure of the gauge. Stresses that exceed the cohesive and adhesive strengths of a deposit were used to explore in more detail the adhesive properties of foulant layers, using dried tomato purée as a model system. A quasi-stagnant system was used, in which the only flow present was that through the gauge. Thus the gauge was the source of all stresses imposed on the deposit by flow; this enabled accurate inference of the imposed normal stress.

Published
2006

20. Surgery for constipation: systematic review and clinical guidance: Paper 1: Introduction & Methods

Author

Knowles, C. H., Grossi, U., Horrocks, E. J., Pares, D., Vollebregt, P. F., Chapman, M., Brown, S. R., Mercer‐Jones, M., Williams, A. B., Hooper, R. J., Stevens, N., Mason, J., Campbell, Kenneth, Clarke, Andrew, Cruickshank, Neil, Dixon, Anthony, Emmett, Christopher, Lacy‐Colson, Jon, Lindsey, Ian, Miller, Andrew, Pilkington, Sophie, Smart, Neil, Tincello, Douglas, Telford, Karen, Yiannakou, Yan, Altomare, Donato, Boenicke, Lars, Buntzen, Steen, Campbell, Ken, Christensen, Peter, DʼHoore, Andre, Espin, Eloy, Jayne, David, Jones, Oliver, Knapp, Jens‐Christian, Laurberg, Soren, Lehur, Paul, Matzel, Klaus, OʼConnell, Ronan, Prudʼhomme, Michel, Ratto, Carlo, Trompetto, Mario, and Vaizey, Caroline

Published
2017
Full Text
View/download PDF

21. Surgery for constipation: systematic review and practice recommendations: Graded practice and future research recommendations

Author

Knowles, C. H., Grossi, U., Horrocks, E. J., Pares, D., Vollebregt, P. F., Chapman, M., Brown, S., Mercer‐Jones, M., Williams, A. B., Yiannakou, Y., Hooper, R. J., Stevens, N., Mason, J., Campbell, Kenneth, Clarke, Andrew, Cruickshank, Neil, Dixon, Anthony, Emmett, Christopher, Lacy‐Colson, Jon, Lindsey, Ian, Miller, Andrew, Pilkington, Sophie, Smart, Neil, Tincello, Douglas, Telford, Karen, Altomare, Donato, Boenicke, Lars, Buntzen, Steen, Campbell, Ken, Christensen, Peter, DʼHoore, Andre, Espin, Eloy, Jayne, David, Jones, Oliver, Knapp, Jens‐Christian, Laurberg, Soren, Lehur, Paul, Matzel, Klaus, OʼConnell, Ronan, Prudhomme, Michel, Ratto, Carlo, Trompetto, Mario, and Vaizey, Carolynne

Published
2017
Full Text
View/download PDF

23. Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy

Author

Colin H. Quinn, Andee M. Beierle, Sara Claire Hutchins, Raoud Marayati, Laura V. Bownes, Jerry E. Stewart, Hooper R. Markert, Michael H. Erwin, Jamie M. Aye, Karina J. Yoon, Gregory K. Friedman, Christopher D. Willey, James M. Markert, and Elizabeth A. Beierle

Subjects
Cancer Research, neuroblastoma, Oncology, oncolytic viruses, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, immunotherapy, three-dimensional printing, patient-derived xenografts, RC254-282
Abstract

Cancer is the leading cause of death by disease in children, and over 15% of pediatric cancer-related mortalities are due to neuroblastoma. Current treatment options for neuroblastoma remain suboptimal as they often have significant toxicities, are associated with long-term side effects, and result in disease relapse in over half of children with high-risk disease. There is a dire need for new therapies, and oncolytic viruses may represent an effective solution. Oncolytic viruses attack tumor cells in two ways: direct infection of tumor cells leading to cytolysis, and production of a debris field that stimulates an anti-tumor immune response. Our group has previously shown that M002, an oncolytic herpes simplex virus (oHSV), genetically engineered to express murine interleukin-12 (mIL-12), was effective at targeting and killing long term passage tumor cell lines. In the current study, we investigated M002 in three neuroblastoma patient-derived xenografts (PDXs). PDXs better recapitulate the human condition, and these studies were designed to gather robust data for translation to a clinical trial. We found that all three PDXs expressed viral entry receptors, and that the virus actively replicated in the cells. M002 caused significant tumor cell death in 2D culture and 3D bioprinted tumor models. Finally, the PDXs displayed variable susceptibility to M002, with a more profound effect on high-risk neuroblastoma PDXs compared to low-risk PDX. These findings validate the importance of incorporating PDXs for preclinical testing of oncolytic viral therapeutics and showcase a novel technique, 3D bioprinting, to test therapies in PDXs. Collectively, our data indicate that oHSVs effectively target high-risk neuroblastoma, and support the advancement of this therapy to the clinical setting.

Published
2022
Full Text
View/download PDF

25. Meta‐analysis of individual‐patient data from EVAR‐1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years

Author

Powell, J. T., Sweeting, M. J., Ulug, P., Blankensteijn, J. D., Lederle, F. A., Becquemin, J.‐P., Greenhalgh, R. M., Greenhalgh, R. M., Beard, J. D., Buxton, M. J., Brown, L. C., Harris, P. L., Powell, J. T., Rose, J. D. G., Russell, I. T., Sculpher, M. J., Thompson, S. G., Lilford, R.J., Bell, P. R. F., Greenhalgh, R. M., Whitaker, S.C., Poole‐Wilson, the late P.A., Ruckley, C. V., Campbell, W. B., Dean, M. R. E., Ruttley, M. S. T., Coles, E. C., Powell, J. T., Halliday, A., Gibbs, S. J., Brown, L. C., Epstein, D., Sculpher, M. J., Thompson, S. G., Hannon, R. J., Johnston, L., Bradbury, A. W., Henderson, M. J., Parvin, S. D., Shepherd, D. F. C., Greenhalgh, R. M., Mitchell, A. W., Edwards, P. R., Abbott, G. T., Higman, D. J., Vohra, A., Ashley, S., Robottom, C., Wyatt, M. G., Rose, J. D. G., Byrne, D., Edwards, R., Leiberman, D. P., McCarter, D. H., Taylor, P. R., Reidy, J. F., Wilkinson, A. R., Ettles, D. F., Clason, A. E., Leen, G. L. S., Wilson, N. V., Downes, M., Walker, S. R., Lavelle, J. M., Gough, M. J., McPherson, S., Scott, D. J. A., Kessell, D. O., Naylor, R., Sayers, R., Fishwick, N. G., Harris, P. L., Gould, D. A., Walker, M. G., Chalmers, N. C., Garnham, A., Collins, M. A., Beard, J. D., Gaines, P. A., Ashour, M. Y., Uberoi, R., Braithwaite, B., Whitaker, S. C., Davies, J. N., Travis, S., Hamilton, G., Platts, A., Shandall, A., Sullivan, B. A., Sobeh, M., Matson, M., Fox, A. D., Orme, R., Yusef, W., Doyle, T., Horrocks, M., Hardman, J., Blair, P. H. B., Ellis, P. K., Morris, G., Odurny, A., Vohra, R., Duddy, M., Thompson, M., Loosemore, T. M. L., Belli, A. M., Morgan, R., Adiseshiah, M., Brookes, J. A. S., McCollum, C. N., Ashleigh, R., Aukett, M., Baker, S., Barbe, E., Batson, N., Bell, J., Blundell, J., Boardley, D., Boyes, S., Brown, O., Bryce, J., Carmichael, M., Chance, T., Coleman, J., Cosgrove, C., Curran, G., Dennison, T., Devine, C., Dewhirst, N., Errington, B., Farrell, H., Fisher, C., Fulford, P., Gough, M., Graham, C., Hooper, R., Horne, G., Horrocks, L., Hughes, B., Hutchings, T., Ireland, M., Judge, C., Kelly, L., Kemp, J., Kite, A., Kivela, M., Lapworth, M., Lee, C., Linekar, L., Mahmood, A., March, L., Martin, J., Matharu, N., McGuigen, K., Morris‐Vincent, P., Murray, S., Murtagh, A., Owen, G., Ramoutar, V., Rippin, C., Rowley, J., Sinclair, J., Spencer, S., Taylor, V., Tomlinson, C., Ward, S., Wealleans, V., West, J., White, K., Williams, J., Wilson, L., Grobbee, D. E., Blankensteijn, J. D., Bak, A. A. A., Buth, J., Pattynama, P. M., Verhoeven, E. L. G., van Voorthuisen, A. E., Blankensteijn, J. D., Balm, R., Buth, J., Cuypers, P. W. M., Grobbee, D. E., Prinssen, M., van Sambeek, M. R. H. M., Verhoeven, E. L. G., Baas, A. F., Hunink, M. G., van Engelshoven, J. M., Jacobs, M. J. H. M., de Mol, B. A. J. M., van Bockel, J. H., Balm, R., Reekers, J., Tielbeek, X., Verhoeven, E. L. G., Wisselink, W., Boekema, N., Heuveling, L. M., Sikking, I., Prinssen, M., Balm, R., Blankensteijn, J. D., Buth, J., Cuypers, P. W. M., van Sambeek, M. R. H. M., Verhoeven, E. L. G., de Bruin, J. L., Baas, A. F., Blankensteijn, J. D., Prinssen, M., Buth, J., Tielbeek, A.V., Blankensteijn, J. D., Balm, R., Reekers, J. A., van Sambeek, M. R. H. M., Pattynama, P., Verhoeven, E. L. G., Prins, T., van der Ham, A. C., van der Velden, J. J. I. M., van Sterkenburg, S. M. M., ten Haken, G. B., Bruijninckx, C. M. A., van Overhagen, H., Tutein Nolthenius, R. P., Hendriksz, T. R., Teijink, J. A. W., Odink, H. F., de Smet, A. A. E. A., Vroegindeweij, D., van Loenhout, R. M. M., Rutten, M. J., Hamming, J. F., Lampmann, L. E. H., Bender, M. H. M., Pasmans, H., Vahl, A. C., de Vries, C., Mackaay, A. J. C., van Dortmont, L. M. C., van der Vliet, A. J., Schultze Kool, L. J., Boomsma, J. H. B., van Dop, H. R., de Mol van Otterloo, J. C. A., de Rooij, T. P. W., Smits, T. M., Yilmaz, E. N., Wisselink, W., van den Berg, F. G., Visser, M. J. T., van der Linden, E., Schurink, G. W. H., de Haan, M., Smeets, H. J., Stabel, P., van Elst, F., Poniewierski, J., Vermassen, F. E. G., Lederle, F. A., Freischlag, J. A., Kohler, T. R., Latts, E., Matsumura, J., Padberg, F. T., Jr, Kyriakides, T. C., Swanson, K. M., Guarino, P., Peduzzi, P., Antonelli, M., Cushing, C., Davis, E., Durant, L., Joyner, S., Kossack, the late A., Kyriakides, T. C., LeGwin, Mary, McBride, V., OʼConnor, T., Poulton, J., Stratton, the late S., Zellner, S., Snodgrass, A. J., Thornton, J., Swanson, K. M., Haakenson, C. M., Stroupe, K.T., Jonk, Y., Hallett, J. W., Hertzer, N., Towne, J., Katz, D. A., Karrison, T., Matts, J. P., Marottoli, R., Kasl, S., Mehta, R., Feldman, R., Farrell, W., Allore, H., Perry, E., Niederman, J., Randall, F., Zeman, M., Beckwith, the late D., OʼLeary, T. J., Huang, G. D., Latts, E., Bader, M., Ketteler, E. R., Kingsley, D. D., Marek, J. M., Massen, R. J., Matteson, B. D., Pitcher, J. D., Langsfeld, M., Corson, J. D., Goff, J. M., Jr, Kasirajan, K., Paap, C., Robertson, D. C., Salam, A., Veeraswamy, R., Milner, R., Kasirajan, K., Guidot, J., Lal, B. K., Busuttil, S. J., Lilly, M. P., Braganza, M., Ellis, K., Patterson, M. A., Jordan, W. D., Whitley, D., Taylor, S., Passman, M., Kerns, D., Inman, C., Poirier, J., Ebaugh, J., Raffetto, J., Chew, D., Lathi, S., Owens, C., Hickson, K., Dosluoglu, H. H., Eschberger, K., Kibbe, M. R., Baraniewski, H. M., Matsumura, J., Endo, M., Busman, A., Meadows, W., Evans, M., Giglia, J. S., El Sayed, H., Reed, A. B., Ruf, M., Ross, S., Jean‐Claude, J. M., Pinault, G., Kang, P., White, N., Eiseman, M., Jones, the late R., Timaran, C. H., Modrall, J. G., Welborn, M. B., III, Lopez, J., Nguyen, T., Chacko, J. K. Y., Granke, K., Vouyouka, A. G., Olgren, E., Chand, P., Allende, B., Ranella, M., Yales, C., Whitehill, T. A., Krupski, the late W. C., Nehler, M. R., Johnson, S. P., Jones, D. N., Strecker, P., Bhola, M. A., Shortell, C. K., Gray, J. L., Lawson, J. H., McCann, R., Sebastian, M.W., Kistler Tetterton, J., Blackwell, C., Prinzo, P. A., Lee, N., Padberg, F. T., Jr, Cerveira, J. J., Lal, B. K., Zickler, R. W., Hauck, K. A., Berceli, S. A., Lee, W. A., Ozaki, C. K., Nelson, P. R., Irwin, A. S., Baum, R., Aulivola, B., Rodriguez, H., Littooy, F. N., Greisler, H., OʼSullivan, M. T., Kougias, P., Lin, P. H., Bush, R. L., Guinn, G., Bechara, C., Cagiannos, C., Pisimisis, G., Barshes, N., Pillack, S., Guillory, B., Cikrit, D., Lalka, S. G., Lemmon, G., Nachreiner, R., Rusomaroff, M., OʼBrien, E., Cullen, J. J., Hoballah, J., Sharp, W. J., McCandless, J. L., Beach, V., Minion, D., Schwarcz, T. H., Kimbrough, J., Ashe, L., Rockich, A., Warner‐Carpenter, J., Moursi, M., Eidt, J. F., Brock, S., Bianchi, C., Bishop, V., Gordon, I. L., Fujitani, R., Kubaska, S. M., III, Behdad, M., Azadegan, R., Ma Agas, C., Zalecki, K., Hoch, J. R., Carr, S. C., Acher, C., Schwarze, M., Tefera, G., Mell, M., Dunlap, B., Rieder, J., Stuart, J. M., Weiman, D. S., Abul‐Khoudoud, O., Garrett, H. E., Walsh, S. M., Wilson, K. L., Seabrook, G. R., Cambria, R. A., Brown, K. R., Lewis, B. D., Framberg, S., Kallio, C., Barke, R. A., Santilli, S. M., dʼAudiffret, A. C., Oberle, N., Proebstle, C., Johnson, L. L., Jacobowitz, G. R., Cayne, N., Rockman, C., Adelman, M., Gagne, P., Nalbandian, M., Caropolo, L. J., Pipinos, I. I., Johanning, J., Lynch, T., DeSpiegelaere, H., Purviance, G., Zhou, W., Dalman, R., Lee, J. T., Safadi, B., Coogan, S. M., Wren, S. M., Bahmani, D. D., Maples, D., Thunen, S., Golden, M. A., Mitchell, M. E., Fairman, R., Reinhardt, S., Wilson, M. A., Tzeng, E., Muluk, S., Peterson, N. M., Foster, M., Edwards, J., Moneta, G. L., Landry, G., Taylor, L., Yeager, R., Cannady, E., Treiman, G., Hatton‐Ward, S., Salabsky, the late B., Kansal, N., Owens, E., Estes, M., Forbes, B. A., Sobotta, C., Rapp, J. H., Reilly, L. M., Perez, S. L., Yan, K., Sarkar, R., Dwyer, S. S., Perez, S., Chong, K., Kohler, T. R., Hatsukami, T. S., Glickerman, D. G., Sobel, M., Burdick, T. S., Pedersen, K., Cleary, P., Back, M., Bandyk, D., Johnson, B., Shames, M., Reinhard, R. L., Thomas, S. C., Hunter, G. C., Leon, L. R., Jr, Westerband, A., Guerra, R. J., Riveros, M., Mills, J. L., Sr, Hughes, J. D., Escalante, A. M., Psalms, S. B., Day, N. N., Macsata, R., Sidawy, A., Weiswasser, J., Arora, S., Jasper, B. J., Dardik, A., Gahtan, V., Muhs, B. E., Sumpio, B. E., Gusberg, R. J., Spector, M., Pollak, J., Aruny, J., Kelly, E. L., Wong, J., Vasilas, P., Joncas, C., Gelabert, H. A., DeVirgillio, C., Rigberg, D. A., Cole, L., Becquemin, J.‐P., Marzelle, J., Becquemin, J.‐P., Sapoval, M., Becquemin, J.‐P., Favre, J.‐P., Watelet, J., Lermusiaux, P., Sapoval, M., Lepage, E., Hemery, F., Dolbeau, G., Hawajry, N., Cunin, P., Harris, P., Stockx, L., Chatellier, G., Mialhe, C., Fiessinger, J.‐N., Pagny, L., Kobeiter, H., Boissier, C., Lacroix, P., Ledru, F., Pinot, J.‐J., Deux, J.‐F., Tzvetkov, B., Duvaldestin, P., Watelet, J., Jourdain, C., David, V., Enouf, D., Ady, N., Krimi, A., Boudjema, N., Jousset, Y., Enon, B., Blin, V., Picquet, J., LʼHoste, P., Thouveny, F., Borie, H., Kowarski, S., Pernes, J.‐M., Auguste, M., Becquemin, J.‐P., Desgranges, P., Allaire, E., Marzelle, J., Kobeiter, H., Meaulle, P.‐Y., Chaix, D., Juliae, P., Fabiani, J. N., Chevalier, P., Combes, M., Seguin, A., Belhomme, D., Sapoval, M., Baque, J., Pellerin, O., Favre, J. P., Barral, X., Veyret, C., Watelet, J., Peillon, C., Plissonier, D., Thomas, P., Clavier, E., Lermusiaux, P., Martinez, R., Bleuet, F., C, Dupreix, Verhoye, J. P., Langanay, T., Heautot, J. F., Koussa, M., Haulon, S., Halna, P., Destrieux, L., Lions, C., Wiloteaux, S., Beregi, J. P., Bergeron, P., Pinot, J.‐J., Patra, P., Costargent, A., Chaillou, P., DʼAlicourt, A., Goueffic, Y., Cheysson, E., Parrot, A., Garance, P., Demon, A., Tyazi, A., Pillet, J.‐C., Lescalie, F., Tilly, G., Steinmetz, E., Favier, C., Brenot, R., Krause, D., Cercueil, J. P., Vahdat, O., Sauer, M., Soula, P., Querian, A., Garcia, O., Levade, M., Colombier, D., Cardon, J.‐M., Joyeux, A., Borrelly, P., Dogas, G., Magnan, P.‐É., Branchereau, A., Bartoli, J.‐M., Hassen‐Khodja, R., Batt, M., Planchard, P.‐F., Bouillanne, P.‐J., Haudebourg, P., Bayne, J., Gouny, P., Badra, A., Braesco, J., Nonent, M., Lucas, A., Cardon, A., Kerdiles, Y., Rolland, Y., Kassab, M., Brillu, C., Goubault, F., Tailboux, L., Darrieux, H., Briand, O., Maillard, J.‐C., Varty, K., and Cousins, C.

Published
2017
Full Text
View/download PDF

29. Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

Author

Andee M. Beierle, Colin H. Quinn, Elizabeth Mroczek-Musulman, Jamie M. Aye, David K. Crossman, Adele P. Williams, Hooper R. Markert, Jerry E. Stewart, Raoud Marayati, Karina J. Yoon, Laura V. Bownes, and Elizabeth A. Beierle

Subjects
0301 basic medicine, MAPK/ERK pathway, Cancer Research, medicine.medical_treatment, Receptor expression, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, Crizotinib, Neuroendocrine tumor, In vivo, medicine, RC254-282, Original Research, business.industry, Sunitinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Drug resistance, Cancer research, business, Patient derived xenoline, TYRO3, medicine.drug
Abstract

Highlights • Rare, high grade neuroendocrine-like pediatric tumor has TYRO3 and ALK mutations. • Crizotinib downregulates STAT3 and ERK1/2 signaling in tumor. • In vivo analysis demonstrated crizotinib resistance. • Crizotinib resistant cells have upregulation of PDGFRß signaling. • PDGFRß inhibition overrides resistance., Patient-derived xenografts provide significant advantages over long-term passage cell lines when investigating efficacy of treatments for solid tumors. Our laboratory encountered a high-grade, metastatic, neuroendocrine-like tumor from a pediatric patient that presented with a unique genetic profile. In particular, mutations in TYRO3 and ALK were identified. We established a human patient-derived xenoline (PDX) of this tumor for use in the current study. We investigated the effect of crizotinib, a chemotherapeutic known to effectively target both TYRO3 and ALK mutations. Crizotinib effectively decreased viability, proliferation, growth, and the metastatic properties of the PDX tumor through downregulation of STAT3 signaling, but expression of PDGFRß was increased. Sunitinib is a small molecule inhibitor of PDGFRß and was studied in this PDX independently and in combination with crizotinib. Sunitinib alone decreased viability, proliferation, and growth in vitro and decreased tumor growth in vivo. In combination, sunitinib was able to overcome potential crizotinib-induced resistance through downregulation of ERK 1/2 activity and PDGFRß receptor expression; consequently, tumor growth was significantly decreased both in vitro and in vivo. Through the use of the PDX, it was possible to identify crizotinib as a less effective therapeutic for this tumor and suggest that targeting PDGFRß would be more effective. These findings may translate to other solid tumors that present with the same genetic mutations.

Published
2021

38. Use of a common food frequency questionnaire (FFQ) to assess dietary patterns and their relation to allergy and asthma in Europe: pilot study of the GA2LEN FFQ

Author

Garcia-Larsen, V, Luczynska, M, Kowalski, M L, Voutilainen, H, Ahlström, M, Haahtela, T, Toskala, E, Bockelbrink, A, Lee, H-H, Vassilopoulou, E, Papadopoulos, N G, Ramalho, R, Moreira, A, Delgado, L, Castel-Branco, M G, Calder, P C, Childs, C E, Bakolis, I, Hooper, R, and Burney, P G

Published
2011
Full Text
View/download PDF

40. Non-randomised studies should be considered for assessing surgical techniques in rectal prolapse : prospective cohort study

Author

Lee, M., Dimairo, M., Edwards, J., Hawkins, D., Hind, D., Knowles, C., Hooper, R., and Brown, S.

Abstract

Objectives\ud \ud Randomised trials comparing surgical techniques for rectal prolapse are not always feasible. We assessed whether non‐randomised comparisons of those who have had surgery with those still waiting would be confounded baseline health status.\ud \ud \ud \ud Study Design and Setting\ud \ud \ud \ud Prospective cohort study in seven UK hospitals. Participants ≥18 years listed for surgical interventions of equivalent intensity for rectal prolapse. Participants were defined as short or long waiters (≤ or >18 weeks, respectively). Time on the waiting list was compared with baseline comorbidity (Charlson Comorbidity Index, CCI) and change from baseline in health status (EQ‐5D‐5L) at the time of surgery.\ud \ud \ud \ud Results\ud \ud 203 patients were analysed. Median (IQR) waiting time was 13.7 weeks (8.1, 20.4) varying across sites. Baseline comorbidity was not an important predictor of waiting time. Median CCI was 2 (0, 3) for short and 1 (0, 3) for long waiters. A change in waiting time by a week was associated with negligible improvement in EQ‐5D‐5L index of 0.001 (95%CI: ‐0.000 to 0.003, p =0.106).\ud \ud \ud \ud Conclusion\ud \ud Negligible change in patient reported health status while on waiting list and lack of effect of comorbidities in influencing waiting time supports the use of non‐randomised pre‐/post‐study to compare the effects of surgical interventions for rectal prolapse.

Published
2020

41. Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

Author

Adele P. Williams, Jamie M. Aye, Laura L. Stafman, Alicia M. Waters, Evan F. Garner, Elizabeth A. Beierle, Hooper R. Markert, and Jerry E. Stewart

Subjects
0301 basic medicine, Cancer Research, Original article, Phosphatase, Endogeny, macromolecular substances, environment and public health, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, In vivo, Neuroblastoma, medicine, Viability assay, Chemistry, Activator (genetics), Protein phosphatase 2, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, enzymes and coenzymes (carbohydrates), 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, embryonic structures, Cancer research
Abstract

High-risk neuroblastoma continues to carry a poor prognosis. Nearly 50% of these tumors relapse following extensive treatment regimens. Protein phosphatase 2A (PP2A), a tumor suppressor, has been shown to be downregulated in many human cancers via multiple mechanisms including upregulation of its endogenous inhibitors, I2PP2A or CIP2A. We hypothesized that inhibition of the endogenous PP2A inhibitors or activation of PP2A would decrease tumorigenicity in human neuroblastoma cells. Four human neuroblastoma cell lines were utilized. Expression of PP2A and its endogenous inhibitors I2PP2A and CIP2A was confirmed by immunoblotting. PP2A activation was measured via phosphatase activation assay. Multiple parallel methods including siRNA inhibition of the endogenous PP2A inhibitors and pharmacologic activation of PP2A were utilized. Cell viability, proliferation, migration, and invasion assays were performed. In vivo studies were utilized to determine the effects of PP2A activation on neuroblastoma tumor growth. Inhibition of the endogenous inhibitors of PP2A or pharmacologic activation of PP2A with the PP2A activator FTY720 led to decreased neuroblastoma cell viability, proliferation, migration, and invasion. Treatment of mice bearing SK-N-AS or SK-N-BE(2) neuroblastoma tumors with FTY720 resulted in a significant decrease in tumor growth compared to vehicle-treated animals. In conclusion, activation of PP2A may provide a novel therapeutic target for neuroblastoma.

Published
2019

46. The upgraded DØ detector

Author

Abazov, V.M., Abbott, B., Abolins, M., Acharya, B.S., Adams, D.L., Adams, M., Adams, T., Agelou, M., Agram, J.-L., Ahmed, S.N., Ahn, S.H., Ahsan, M., Alexeev, G.D., Alkhazov, G., Alton, A., Alverson, G., Alves, G.A., Anastasoaie, M., Andeen, T., Anderson, J.T., Anderson, S., Andrieu, B., Angstadt, R., Anosov, V., Arnoud, Y., Arov, M., Askew, A., Åsman, B., Assis Jesus, A.C.S., Atramentov, O., Autermann, C., Avila, C., Babukhadia, L., Bacon, T.C., Badaud, F., Baden, A., Baffioni, S., Bagby, L., Baldin, B., Balm, P.W., Banerjee, P., Banerjee, S., Barberis, E., Bardon, O., Barg, W., Bargassa, P., Baringer, P., Barnes, C., Barreto, J., Bartlett, J.F., Bassler, U., Bhattacharjee, M., Baturitsky, M.A., Bauer, D., Bean, A., Baumbaugh, B., Beauceron, S., Begalli, M., Beaudette, F., Begel, M., Bellavance, A., Beri, S.B., Bernardi, G., Bernhard, R., Bertram, I., Besançon, M., Besson, A., Beuselinck, R., Beutel, D., Bezzubov, V.A., Bhat, P.C., Bhatnagar, V., Binder, M., Biscarat, C., Bishoff, A., Black, K.M., Blackler, I., Blazey, G., Blekman, F., Blessing, S., Bloch, D., Blumenschein, U., Bockenthien, E., Bodyagin, V., Boehnlein, A., Boeriu, O., Bolton, T.A., Bonamy, P., Bonifas, D., Borcherding, F., Borissov, G., Bos, K., Bose, T., Boswell, C., Bowden, M., Brandt, A., Briskin, G., Brock, R., Brooijmans, G., Bross, A., Buchanan, N.J., Buchholz, D., Buehler, M., Buescher, V., Burdin, S., Burke, S., Burnett, T.H., Busato, E., Buszello, C.P., Butler, D., Butler, J.M., Cammin, J., Caron, S., Bystricky, J., Canal, L., Canelli, F., Carvalho, W., Casey, B.C.K., Casey, D., Cason, N.M., Castilla-Valdez, H., Chakrabarti, S., Chakraborty, D., Chan, K.M., Chandra, A., Chapin, D., Charles, F., Cheu, E., Chevalier, L., Chi, E., Chiche, R., Cho, D.K., Choate, R., Choi, S., Choudhary, B., Chopra, S., Christenson, J.H., Christiansen, T., Christofek, L., Churin, I., Cisko, G., Claes, D., Clark, A.R., Clément, B., Clément, C., Coadou, Y., Colling, D.J., Coney, L., Connolly, B., Cooke, M., Cooper, W.E., Coppage, D., Corcoran, M., Coss, J., Cothenet, A., Cousinou, M.-C., Cox, B., Crépé-Renaudin, S., Cristetiu, M., Cummings, M.A.C., Cutts, D., da Motta, H., Das, M., Davies, B., Davies, G., Davis, G.A., Davis, W., De, K., de Jong, P., de Jong, S.J., De La Cruz-Burelo, E., De La Taille, C., De Oliveira Martins, C., Dean, S., Degenhardt, J.D., Déliot, F., Delsart, P.A., Del Signore, K., DeMaat, R., Demarteau, M., Demina, R., Demine, P., Denisov, D., Denisov, S.P., Desai, S., Diehl, H.T., Diesburg, M., Doets, M., Doidge, M., Dong, H., Doulas, S., Dudko, L.V., Duflot, L., Dugad, S.R., Duperrin, A., Dvornikov, O., Dyer, J., Dyshkant, A., Eads, M., Edmunds, D., Edwards, T., Ellison, J., Elmsheuser, J., Eltzroth, J.T., Elvira, V.D., Eno, S., Ermolov, P., Eroshin, O.V., Estrada, J., Evans, D., Evans, H., Evdokimov, A., Evdokimov, V.N., Fagan, J., Fast, J., Fatakia, S.N., Fein, D., Feligioni, L., Ferapontov, A.V., Ferbel, T., Ferreira, M.J., Fiedler, F., Filthaut, F., Fisher, W., Fisk, H.E., Fleck, I., Fitzpatrick, T., Flattum, E., Fleuret, F., Flores, R., Foglesong, J., Fortner, M., Fox, H., Franklin, C., Freeman, W., Fu, S., Fuess, S., Gadfort, T., Galea, C.F., Gallas, E., Galyaev, E., Gao, M., Garcia, C., Garcia-Bellido, A., Gardner, J., Gavrilov, V., Gay, A., Gay, P., Gelé, D., Gelhaus, R., Genser, K., Gerber, C.E., Gershtein, Y., Gillberg, D., Geurkov, G., Ginther, G., Gobbi, B., Goldmann, K., Golling, T., Gollub, N., Golovtsov, V., Gómez, B., Gomez, G., Gomez, R., Goodwin, R., Gornushkin, Y., Gounder, K., Goussiou, A., Graham, D., Graham, G., Grannis, P.D., Gray, K., Greder, S., Green, D.R., Green, J., Green, J.A., Greenlee, H., Greenwood, Z.D., Gregores, E.M., Grinstein, S., Gris, Ph., Grivaz, J.-F., Groer, L., Grünendahl, S., Grünewald, M.W., Gu, W., Guglielmo, J., Gupta, A., Gurzhiev, S.N., Gutierrez, G., Gutierrez, P., Haas, A., Hadley, N.J., Haggard, E., Haggerty, H., Hagopian, S., Hall, I., Hall, R.E., Han, C., Han, L., Hance, R., Hanagaki, K., Hanlet, P., Hansen, S., Harder, K., Harel, A., Harrington, R., Hauptman, J.M., Hauser, R., Hays, C., Hays, J., Hazen, E., Hebbeker, T., Hebert, C., Hedin, D., Heinmiller, J.M., Heinson, A.P., Heintz, U., Hensel, C., Hesketh, G., Hildreth, M.D., Hirosky, R., Hobbs, J.D., Hoeneisen, B., Hohlfeld, M., Hong, S.J., Hooper, R., Hou, S., Houben, P., Hu, Y., Huang, J., Huang, Y., Hynek, V., Huffman, D., Iashvili, I., Illingworth, R., Ito, A.S., Jabeen, S., Jacquier, Y., Jaffré, M., Jain, S., Jain, V., Jakobs, K., Jayanti, R., Jenkins, A., Jesik, R., Jiang, Y., Johns, K., Johnson, M., Johnson, P., Jonckheere, A., Jonsson, P., Jöstlein, H., Jouravlev, N., Juarez, M., Juste, A., Kaan, A.P., Kado, M.M., Käfer, D., Kahl, W., Kahn, S., Kajfasz, E., Kalinin, A.M., Kalk, J., Kalmani, S.D., Karmanov, D., Kasper, J., Katsanos, I., Kau, D., Kaur, R., Ke, Z., Kehoe, R., Kermiche, S., Kesisoglou, S., Khanov, A., Kharchilava, A., Kharzheev, Y.M., Kim, H., Kim, K.H., Kim, T.J., Kirsch, N., Klima, B., Klute, M., Kohli, J.M., Konrath, J.-P., Komissarov, E.V., Kopal, M., Korablev, V.M., Kostritski, A., Kotcher, J., Kothari, B., Kotwal, A.V., Koubarovsky, A., Kozelov, A.V., Kozminski, J., Kryemadhi, A., Kouznetsov, O., Krane, J., Kravchuk, N., Krempetz, K., Krider, J., Krishnaswamy, M.R., Krzywdzinski, S., Kubantsev, M., Kubinski, R., Kuchinsky, N., Kuleshov, S., Kulik, Y., Kumar, A., Kunori, S., Kupco, A., Kurča, T., Kvita, J., Kuznetsov, V.E., Kwarciany, R., Lager, S., Lahrichi, N., Landsberg, G., Larwill, M., Laurens, P., Lavigne, B., Lazoflores, J., Le Bihan, A.-C., Le Meur, G., Lebrun, P., Lee, S.W., Lee, W.M., Leflat, A., Leggett, C., Lehner, F., Leitner, R., Leonidopoulos, C., Leveque, J., Lewis, P., Li, J., Li, Q.Z., Li, X., Lima, J.G.R., Lincoln, D., Lindenmeyer, C., Linn, S.L., Linnemann, J., Lipaev, V.V., Lipton, R., Litmaath, M., Lizarazo, J., Lobo, L., Lobodenko, A., Lokajicek, M., Lounis, A., Love, P., Lu, J., Lubatti, H.J., Lucotte, A., Lueking, L., Luo, C., Lynker, M., Lyon, A.L., Machado, E., Maciel, A.K.A., Madaras, R.J., Mättig, P., Magass, C., Magerkurth, A., Magnan, A.-M., Maity, M., Makovec, N., Mal, P.K., Malbouisson, H.B., Malik, S., Malyshev, V.L., Manakov, V., Mao, H.S., Maravin, Y., Markley, D., Markus, M., Marshall, T., Martens, M., Martin, M., Martin-Chassard, G., Mattingly, S.E.K., Matulik, M., Mayorov, A.A., McCarthy, R., McCroskey, R., McKenna, M., McMahon, T., Meder, D., Melanson, H.L., Melnitchouk, A., Mendes, A., Mendoza, D., Mendoza, L., Meng, X., Merekov, Y.P., Merkin, M., Merritt, K.W., Meyer, A., Meyer, J., Michaut, M., Miao, C., Miettinen, H., Mihalcea, D., Mikhailov, V., Miller, D., Mitrevski, J., Mokhov, N., Molina, J., Mondal, N.K., Montgomery, H.E., Moore, R.W., Moulik, T., Muanza, G.S., Mostafa, M., Moua, S., Mulders, M., Mundim, L., Mutaf, Y.D., Nagaraj, P., Nagy, E., Naimuddin, M., Nang, F., Narain, M., Narasimhan, V.S., Narayanan, A., Naumann, N.A., Neal, H.A., Negret, J.P., Nelson, S., Neuenschwander, R.T., Neustroev, P., Noeding, C., Nomerotski, A., Novaes, S.F., Nozdrin, A., Nunnemann, T., Nurczyk, A., Nurse, E., O’Dell, V., O’Neil, D.C., Oguri, V., Olis, D., Oliveira, N., Olivier, B., Olsen, J., Oshima, N., Oshinowo, B.O., Otero y Garzón, G.J., Padley, P., Papageorgiou, K., Parashar, N., Park, J., Park, S.K., Parsons, J., Partridge, R., Parua, N., Patwa, A., Pawloski, G., Perea, P.M., Perez, E., Peters, O., Pétroff, P., Petteni, M., Phaf, L., Piegaia, R., Pleier, M.-A., Podesta-Lerma, P.L.M., Podstavkov, V.M., Pogorelov, Y., Pol, M.-E., Pompoš, A., Polosov, P., Pope, B.G., Popkov, E., Porokhovoy, S., Prado da Silva, W.L., Pritchard, W., Prokhorov, I., Prosper, H.B., Protopopescu, S., Przybycien, M.B., Qian, J., Quadt, A., Quinn, B., Ramberg, E., Ramirez-Gomez, R., Rani, K.J., Ranjan, K., Rao, M.V.S., Rapidis, P.A., Rapisarda, S., Raskowski, J., Ratoff, P.N., Ray, R.E., Reay, N.W., Rechenmacher, R., Reddy, L.V., Regan, T., Renardy, J.-F., Reucroft, S., Rha, J., Ridel, M., Rijssenbeek, M., Ripp-Baudot, I., Rizatdinova, F., Robinson, S., Rodrigues, R.F., Roco, M., Rotolo, C., Royon, C., Rubinov, P., Ruchti, R., Rucinski, R., Rud, V.I., Russakovich, N., Russo, P., Sabirov, B., Sajot, G., Sánchez-Hernández, A., Sanders, M.P., Santoro, A., Satyanarayana, B., Savage, G., Sawyer, L., Scanlon, T., Schaile, D., Schamberger, R.D., Scheglov, Y., Schellman, H., Schieferdecker, P., Schmitt, C., Schwanenberger, C., Schukin, A.A., Schwartzman, A., Schwienhorst, R., Sengupta, S., Severini, H., Shabalina, E., Shamim, M., Shankar, H.C., Shary, V., Shchukin, A.A., Sheahan, P., Shephard, W.D., Shivpuri, R.K., Shishkin, A.A., Shpakov, D., Shupe, M., Sidwell, R.A., Simak, V., Sirotenko, V., Skow, D., Skubic, P., Slattery, P., Smith, D.E., Smith, R.P., Smolek, K., Snow, G.R., Snow, J., Snyder, S., Söldner-Rembold, S., Song, X., Song, Y., Sonnenschein, L., Sopczak, A., Sorín, V., Sosebee, M., Soustruznik, K., Souza, M., Spartana, N., Spurlock, B., Stanton, N.R., Stark, J., Steele, J., Stefanik, A., Steinberg, J., Steinbrück, G., Stevenson, K., Stolin, V., Stone, A., Stoyanova, D.A., Strandberg, J., Strang, M.A., Strauss, M., Ströhmer, R., Strom, D., Strovink, M., Stutte, L., Sumowidagdo, S., Sznajder, A., Talby, M., Tentindo-Repond, S., Tamburello, P., Taylor, W., Telford, P., Temple, J., Terentyev, N., Teterin, V., Thomas, E., Thompson, J., Thooris, B., Titov, M., Toback, D., Tokmenin, V.V., Tolian, C., Tomoto, M., Tompkins, D., Toole, T., Torborg, J., Touze, F., Towers, S., Trefzger, T., Trincaz-Duvoid, S., Trippe, T.G., Tsybychev, D., Tuchming, B., Tully, C., Turcot, A.S., Tuts, P.M., Utes, M., Uvarov, L., Uvarov, S., Uzunyan, S., Vachon, B., van den Berg, P.J., van Gemmeren, P., Van Kooten, R., van Leeuwen, W.M., Varelas, N., Varnes, E.W., Vartapetian, A., Vasilyev, I.A., Vaupel, M., Vaz, M., Verdier, P., Vertogradov, L.S., Verzocchi, M., Vigneault, M., Villeneuve-Seguier, F., Vishwanath, P.R., Vlimant, J.-R., Von Toerne, E., Vorobyov, A., Vreeswijk, M., Vu Anh, T., Vysotsky, V., Wahl, H.D., Walker, R., Wallace, N., Wang, L., Wang, Z.-M., Warchol, J., Warsinsky, M., Watts, G., Wayne, M., Weber, M., Weerts, H., Wegner, M., Wermes, N., Wetstein, M., White, A., White, V., Whiteson, D., Wicke, D., Wijnen, T., Wijngaarden, D.A., Wilcer, N., Willutzki, H., Wilson, G.W., Wimpenny, S.J., Wittlin, J., Wlodek, T., Wobisch, M., Womersley, J., Wood, D.R., Wyatt, T.R., Wu, Z., Xie, Y., Xu, Q., Xuan, N., Yacoob, S., Yamada, R., Yan, M., Yarema, R., Yasuda, T., Yatsunenko, Y.A., Yen, Y., Yip, K., Yoo, H.D., Yoffe, F., Youn, S.W., Yu, J., Yurkewicz, A., Zabi, A., Zanabria, M., Zatserklyaniy, A., Zdrazil, M., Zeitnitz, C., Zhang, B., Zhang, D., Zhang, X., Zhao, T., Zhao, Z., Zheng, H., Zhou, B., Zhu, J., Zielinski, M., Zieminska, D., Zieminski, A., Zitoun, R., Zmuda, T., Zutshi, V., Zviagintsev, S., Zverev, E.G., and Zylberstejn, A.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results